ARCT Insider Trading Activity and SEC Form 4 Filings
ARCT insider trading summary
No open-market insider purchases or sales of Arcturus Therapeutics Holdings Inc. (ARCT) have been reported on SEC Form 4 in the past 12 months.
Latest ARCT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 15, 2025 | Andy Sassine | Chief Financial Officer | Buy | $20K (1,238 @ $16.56) |
| Oct 15, 2024 | Pad Chivukula | Chief Scientific Officer & COO | Sell | $249K (12,000 @ $20.76) |
| Jun 12, 2024 | Andy Sassine | Chief Financial Officer | Sell | $1.6M (50,000 @ $32.03) |
| Jun 5, 2024 | Pad Chivukula | Chief Scientific Officer & COO | Sell | $5K (114 @ $45.00) |
| Jun 3, 2024 | Pad Chivukula | Chief Scientific Officer & COO | Sell | $1.0M (26,000 @ $40.01) |
| Mar 25, 2024 | Pad Chivukula | Chief Scientific Officer & COO | Sell | $611K (17,435 @ $35.02) |
| Mar 19, 2024 | Pad Chivukula | Chief Scientific Officer & COO | Sell | $300K (8,565 @ $35.01) |
| Nov 1, 2023 | Pad Chivukula | Chief Scientific Officer & COO | Sell | $94K (5,000 @ $18.72) |
| Oct 2, 2023 | Pad Chivukula | Chief Scientific Officer & COO | Sell | $128K (5,000 @ $25.61) |
| Sep 1, 2023 | Pad Chivukula | Chief Scientific Officer & COO | Sell | $157K (5,000 @ $31.45) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.